Back to top
more

Myriad Genetics, Inc. (MYGN)

(Delayed Data from NSDQ)

$33.27 USD

33.27
677,000

+0.69 (2.12%)

Updated Dec 13, 2017 03:59 PM ET

Add to portfolio

1-Strong Buy 1        

C Value | D Growth | C Momentum | D VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1 Strong Buy 25.71%
2 Buy 18.12%
3 Hold 9.91%
4 Sell 5.49%
5 Strong Sell 2.29%
S&P 500 9.79%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Balance Sheet

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for MYGN

   

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

Fiscal Year End for Myriad Genetics, Inc. falls in the month of June.

All items in Millions except Per Share data.

6/30/2017 6/30/2016 6/30/2015 6/30/2014 6/30/2013
Assets          
Cash & Equivalents 151 159 145 186 372
Receivables 111 95 88 85 98
Notes Receivable 0 0 0 0 0
Inventories 42 38 25 24 5
Other Current Assets 13 22 26 27 9
Total Current Assets 317 315 284 322 484
Net Property & Equipment 51 58 67 35 28
Investments & Advances 49 80 41 84 159
Other Non-Current Assets 0 0 0 0 22
Deferred Charges 0 0 0 3 29
Intangibles 808 423 370 374 70
Deposits & Other Assets 0 5 5 5 13
Total Assets 1,224 881 766 824 804
Liabilities & Shareholders Equity 6/30/2017 6/30/2016 6/30/2015 6/30/2014 6/30/2013
Notes Payable 0 0 0 0 0
Accounts Payable 22 21 21 23 18
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 66 50 46 56 44
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 130 2 2 1 2
Total Current Liabilities 218 72 69 81 65
Mortgages 0 0 0 0 0
Deferred Taxes/Income 84 18 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 99 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 46 42 35 24 11
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 447 132 104 105 75
Shareholders Equity 6/30/2017 6/30/2016 6/30/2015 6/30/2014 6/30/2013
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 851 830 745 718 697
Retained Earnings -68 -73 -77 2 31
Other Equity -6 -10 -7 -2 -0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 778 748 662 719 729
Total Liabilities & Shareholder's Equity 1,224 881 766 824 804
Total Common Equity 778 748 662 719 729
Shares Outstanding 68.10 70.30 69.40 74.80 79.60
Book Value Per Share 11.42 10.64 9.54 9.61 9.15

Fiscal Year End for Myriad Genetics, Inc. falls in the month of June.

All items in Millions except Per Share data.

9/30/2017 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Assets          
Cash & Equivalents 148 151 172 163 148
Receivables 120 111 119 112 103
Notes Receivable 0 0 0 0 0
Inventories 39 42 47 51 54
Other Current Assets 18 13 10 16 18
Total Current Assets 326 317 348 342 323
Net Property & Equipment 50 51 53 55 57
Investments & Advances 50 49 53 56 52
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 803 808 813 822 834
Deposits & Other Assets 0 0 0 3 5
Total Assets 1,228 1,224 1,268 1,276 1,271
Liabilities & Shareholders Equity 9/30/2017 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Notes Payable 0 0 0 0 199
Accounts Payable 23 22 27 23 20
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 60 66 64 58 55
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 57 130 131 2 1
Total Current Liabilities 139 218 222 83 275
Mortgages 0 0 0 0 0
Deferred Taxes/Income 91 84 85 86 88
Convertible Debt 0 0 0 0 0
Long-Term Debt 74 99 167 204 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 53 46 171 173
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 358 447 520 543 536
Shareholders Equity 9/30/2017 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 860 851 840 832 827
Retained Earnings 13 -68 -81 -86 -87
Other Equity -3 -6 -11 -14 -6
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 871 778 748 733 735
Total Liabilities & Shareholder's Equity 1,228 1,224 1,268 1,276 1,271
Total Common Equity 871 778 748 733 735
Shares Outstanding 69.20 68.10 68.00 68.40 68.70
Book Value Per Share 12.58 11.42 11.00 10.71 10.70